submit to the journals

Myelodysplastic Syndromes Journal Articles, Videos And Insights

Myelodysplastic Syndromes:FEATURED Articles

flipper_slider

Myelodysplastic Syndromes: Latest Articles

Myelodysplastic Syndromes:FEATURED VIDEOS

Editor's choice

Dr. Valeria Santini expounds upon how to understand the efficacy of azacitidine in different myelodysplastic syndromes' (MDS) subgroups.
Study of Azacitidine Combined with Lenalidomide or with Vorinostat Vs. Azacitidine Monotherapy in Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML).

Myelodysplastic Syndromes:Latest Videos

Video List based on Category on Node Page

Latest Videos

Professor Nicolaus Kröger spoke to us at ASH 2018 about the major unmet needs in the treatment of myelodysplastic syndrome in elderly patients, and his phase III study comparing 5-azacytidine induction followed by allogeneic stem cell transplantation versus continuous 5-azacytidine according to...
Dr Naval Daver discusses the use of nivolimumab and ipilimumab in combination with azacitidine in myelodysplastic syndrome and acute myeloid leukemia. FILMED AT THE AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING 2016, SAN DIEGO, CALIFORNIA, US
Adding a second agent to azacitidine for older patients with high-risk myelodysplastic syndrome (MDS) was not found to improve outcomes in the North American Intergroup MDS study, according to Dr Sekeres (Cleveland Clinic, Cleveland, USA) who talked to ecancertv at ASH 2014 about this phase II...
Dr. Valeria Santini expounds upon how to understand the efficacy of azacitidine in different myelodysplastic syndromes' (MDS) subgroups.
Dr. Benjamin Ebert of Brigham and Women's Hospital and a member of the AA&MDSIF Medical Advisory Board, discusses the most important research about MDS (myelodysplastic syndromes) reported at the 2014 American Society of Hematology Annual Meeting. Highlights include genetic mutations and targeting...
Study of Azacitidine Combined with Lenalidomide or with Vorinostat Vs. Azacitidine Monotherapy in Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML).

LATEST TWEETS

Conference Highlights